What We (Don't) Know about the Infectious Disease Burden Among Youth Experiencing Homelessness in the United States and Canada.
Mitra KashaniMichael BienEmily MositesAshley A MeehanPublished in: The Journal of infectious diseases (2024)
Youth experiencing homelessness (YEH) and sexual and gender minority (SGM) YEH may be at increased risk for infectious diseases due to living arrangements, risk behaviors, and barriers to healthcare access that are dissimilar to those of housed youth and older adults experiencing homelessness. To better understand infectious diseases among YEH populations, we synthesized findings from 12 peer-reviewed articles published between 2012 to 2020 which enumerated YEH or SGM YEH infectious disease burden in locations across the U.S. or Canada. Pathogens presented in the studies were limited to sexually transmitted infections (STIs) and bloodborne infections (BBI). Only three studies enumerated infectious diseases among SGM YEH. There was a dearth of comparison data by housing status (ex., sheltered versus unsheltered youth), SGM identity, or other relevant counterfactual groups in the identified studies. We also introduce three publicly available, national-level surveillance datasets from the U.S. or Canada that quantify certain STIs, BBIs, and tuberculosis among YEH, which may be used for future disease burden assessments. Our review calls for more comprehensive YEH-centered research that includes multimodal data collection and timely disease surveillance to improve estimates of infectious diseases among this vulnerable population.
Keyphrases
- infectious diseases
- mental health
- physical activity
- mental illness
- healthcare
- young adults
- case control
- electronic health record
- big data
- risk factors
- systematic review
- mycobacterium tuberculosis
- randomized controlled trial
- current status
- hiv aids
- machine learning
- multidrug resistant
- gram negative
- artificial intelligence
- health information
- antiretroviral therapy
- rna seq
- pulmonary tuberculosis
- adverse drug
- oxide nanoparticles